Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial

PURPOSE: A substantial need for effective and safe treatment options is still unmet for patients with heavily pre-treated human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Herein, we assessed the efficacy and safety of pyrotinib plus trastuzumab and chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xiao-Feng, Zhang, Qiu-Yi, Huang, Jia-Yi, Chen, Li-Ping, Lan, Xiao-Feng, Bai, Xue, Song, Lin, Xiong, Shui-Ling, Guo, Si-Jia, Du, Cai-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823079/
https://www.ncbi.nlm.nih.gov/pubmed/36309908
http://dx.doi.org/10.1007/s10549-022-06770-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823079/
https://www.ncbi.nlm.nih.gov/pubmed/36309908
http://dx.doi.org/10.1007/s10549-022-06770-6

Ejemplares similares